Dr. Gregory Robertson’s research is focused on the field of Mycobacterium tuberculosis host-pathogen interactions with emphasis on the development of novel preclinical tools, use of TB mouse models for drug evaluation, and evaluation of drug activity and resistance in vitro and in vivo. He also leads preclinical animal studies as part of the Consortium for Applied Microbial Metrics including other investigators from the University of California San Francisco, Denver VA Medical Center, and CU Anschutz Medical Campus.
We are looking for talented researchers to join our team!
Contact to Join Our Team
Publications
A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
Ali MZ, Dutt TS, MacNeill A, Walz A, Patterson J, Pearce C, Lam H, Henao-Tamayo M, Lee RE, Liu J, Robertson GT, Hickey AJ, Meibohm B, Gonzalez-Juarrero M.bioRxiv. 2023 Nov 16:2023.11.16.567434. doi: 10.1101/2023.11.16.567434. Preprint. PMID: 38014249
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
Lyons MA, Obregon-Henao A, Ramey ME, Bauman AA, Pauly S, Rossmassler K, Reid J, Karger B, Walter ND, Robertson GT. Antimicrob Agents Chemother. 2024 Mar 19;:e0101023. doi: 10.1128/aac.01010-23. Online ahead of print. PubMed PMID: 38501805.
Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice.
Wynn EA, Dide-Agossou C, Reichlen M, Rossmassler K, Al Mubarak R, Reid JJ, Tabor ST, Born SEM, Ransom MR, Davidson RM, Walton KN, Benoit JB, Hoppers A, Loy DE, Bauman AA, Massoudi LM, Dolganov G, Strong M, Nahid P, Voskuil MI, Robertson GT, Moore CM, Walter ND.mBio. 2023 Oct 31;14(6):e0236323. doi: 10.1128/mbio.02363-23. Online ahead of print. PMID: 37905920
Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
Ramey ME, Kaya F, Bauman AA, Massoudi LM, Sarathy JP, Zimmerman MD, Scott DWL, Job AM, Miller-Dawson JA, Podell BK, Lyons MA, Dartois V, Lenaerts AJ, Robertson GT. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0059723. doi: 10.1128/aac.00597-23. Epub 2023 Oct 4. PMID: 37791784
Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
Walter ND, Ernest JP, Dide-Agossou C, Bauman AA, Ramey ME, Rossmassler K, Massoudi LM, Pauly S, Al Mubarak R, Voskuil MI, Kaya F, Sarathy JP, Zimmerman MD, Dartois V, Podell BK, Savic RM, Robertson GT. Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284-23. Online ahead of print. PMID:37565762
more publications